Glasdegib

Drug Profile

Glasdegib

Alternative Names: Oral Hedgehog Inhibitor - Pfizer; PF 04; PF-04449913; PF-4449913; Smo Inhibitor - Pfizer; Sonic Hedgehog pathway inhibitor (PF 4449913) - Pfizer

Latest Information Update: 09 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Pfizer
  • Developer H. Lee Moffitt Cancer Center and Research Institute; Netherlands Cancer Institute; Pfizer
  • Class Antineoplastics; Benzimidazoles; Phenylurea compounds; Piperidines; Small molecules
  • Mechanism of Action SMO protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Chronic myeloid leukaemia; Colorectal cancer; Myelodysplastic syndromes; Myelofibrosis; Non-small cell lung cancer
  • Phase I/II Chronic myelomonocytic leukaemia
  • Phase I Haematological malignancies
  • No development reported Solid tumours

Most Recent Events

  • 21 Jul 2017 Pfizer completes a phase I bioequivalence trial in Healthy volunteers in USA (PO) (NCT03130556)
  • 09 Jun 2017 Pfizer initiates enrolment in a phase I trial in Healthy volunteers in Belgium (PO) (NCT03162900)
  • 02 Jun 2017 Interim adverse events and efficacy data from a phase I/II trial in Myelofibrosis presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top